恩华药业(002262.SZ)董事会批准2021年度财务预算报告
格隆汇 3 月 11日丨恩华药业(002262.SZ)公布,公司第五届董事会第十五次会议决议,审议通过了《2021年度财务预算报告》。
经对比公司2020年度财务数据,公司在综合考虑了宏观经济形势的复杂多变、国家对医药产业监管力度不断加大、市场竞争日趋激烈、药品带量招标采购、产品降价、成本上升、新型冠状病毒疫情影响等诸多不确定性因素,编制了2021年度财务预算。公司预计2021年可实现业务收入、利润总额及净利润分别与2020年审计后数据同口径相比分别增长10%、20%、20%左右。
上述财务预算、经营计划、经营目标并不代表公司对2021年度的盈利预测,能否实现取决于内外部环境变化等多种因素,存在较大的不确定性,提请投资者特别注意。
该议案尚需提交公司2020年年度股东大会审议表决。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.